Media stories about Foundation Medicine (NASDAQ:FMI) have trended positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.29 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.3288009830248 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment’s analysis:

Shares of Foundation Medicine (NASDAQ:FMI) traded down $3.35 during mid-day trading on Tuesday, hitting $58.90. The company had a trading volume of 461,160 shares, compared to its average volume of 232,024. Foundation Medicine has a 52-week low of $17.10 and a 52-week high of $70.75. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03.

Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.16. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. During the same period last year, the company earned ($0.90) EPS. Foundation Medicine’s quarterly revenue was up 45.0% compared to the same quarter last year. research analysts expect that Foundation Medicine will post -4.43 EPS for the current year.

A number of equities research analysts recently issued reports on FMI shares. Zacks Investment Research lowered Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. BidaskClub lowered Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Foundation Medicine currently has an average rating of “Hold” and an average target price of $43.00.

In other Foundation Medicine news, insider Vincent A. Miller sold 2,944 shares of Foundation Medicine stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $38.80, for a total transaction of $114,227.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jason Ryan sold 3,154 shares of Foundation Medicine stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $38.80, for a total value of $122,375.20. The disclosure for this sale can be found here. Insiders have sold a total of 30,057 shares of company stock valued at $1,301,960 over the last three months. 2.70% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Stock Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related stocks with our FREE daily email newsletter.